Mifepristone: Is there a place in the treatment of Cushing's disease?

Endocrine

Volumn 44, Issue 1, 2013, Pages 20-32

  Carmichael, John D ^a   Fleseriu, Maria ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cushing's disease; Cushing's syndrome; Hypercortisolism; Mifepristone; Pasireotide; Pituitary tumor

Indexed keywords

AMINOGLUTETHIMIDE; CABERGOLINE; DEXAMETHASONE; ETOMIDATE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MITOTANE; PASIREOTIDE; SPIRONOLACTONE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADRENAL INSUFFICIENCY; ADVERSE DRUG REACTION; ALOPECIA; ANOREXIA; ARTHRALGIA; BLEEDING TIME; BLURRED VISION; CHOLELITHIASIS; COMORBIDITY; CUSHING DISEASE; CUSHING SYNDROME; DECREASED APPETITE; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DYSTONIA; ENDOMETRIAL DISEASE; EVIDENCE BASED PRACTICE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HORMONE SYNTHESIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; LETHARGY; LIVER TOXICITY; MYOCLONUS; NAUSEA; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT FAILURE; VOMITING;

ADRENAL GLANDS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; PITUITARY ACTH HYPERSECRETION;

EID: 84881136007     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9846-1     Document Type: Review

References (106)

1. C. Beauregard, G. Dickstein, A. Lacroix, Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy. Treat. Endocrinol. 1(2), 79-94 (2002)
2. B.M. Biller, A.B. Grossman, P.M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A.R. Hermus, L.J. Hofland, A. Klibanski, A. Lacroix, J.R. Lindsay, J. Newell-Price, L.K. Nieman, S. Petersenn, N. Sonino, G.K. Stalla, B. Swearingen, M.L. Vance, J.A. Wass, M. Boscaro, Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 93(7), 2454-2462 (2008). doi: 10.1210/jc.2007-2734
3. A. Colao, R. Pivonello, S. Spiezia, A. Faggiano, D. Ferone, M. Filippella, P. Marzullo, G. Cerbone, M. Siciliani, G. Lombardi, Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J. Clin. Endocrinol. Metab. 84(8), 2664-2672 (1999)
4. M.J. Barahona, N. Sucunza, E. Resmini, J.M. Fernandez-Real, W. Ricart, J.M. Moreno-Navarrete, T. Puig, J. Farrerons, S.M. Webb, Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J. Clin. Endocrinol. Metab. 94(9), 3365-3371 (2009). doi: 10.1210/jc.2009-0766
5. L.D. Dorn, E.S. Burgess, T.C. Friedman, B. Dubbert, P.W. Gold, G.P. Chrousos, The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J. Clin. Endocrinol. Metab. 82(3), 912-919 (1997)
6. J.R. Lindsay, T. Nansel, S. Baid, J. Gumowski, L.K. Nieman, Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J. Clin. Endocrinol. Metab. 91(2), 447-453 (2006). doi: 10.1210/jc.2005-1058
7. T. Mancini, M. Doga, G. Mazziotti, A. Giustina, Cushing's syndrome and bone. Pituitary 7(4), 249-252 (2004). doi: 10.1007/s11102-005-1051-2
8. A.M. Pereira, M.O. van Aken, H. van Dulken, P.J. Schutte, N.R. Biermasz, J.W. Smit, F. Roelfsema, J.A. Romijn, Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J. Clin. Endocrinol. Metab. 88(12), 5858-5864 (2003)
9. N. Sonino, F. Fallo, G.A. Fava, Psychosomatic aspects of Cushing's syndrome. Rev. Endocr. Metab. Disord. 11(2), 95-104 (2010). doi: 10.1007/s11154-009-9123-7
10. G. Mazziotti, C. Gazzaruso, A. Giustina, Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol. Metab. 22(12), 499-506 (2011). doi: 10.1016/j.tem.2011.09.001
11. G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88(12), 5593-5602 (2003)
12. G. Arnaldi, T. Mancini, B. Polenta, M. Boscaro, Cardiovascular risk in Cushing's syndrome. Pituitary 7(4), 253-256 (2004). doi: 10.1007/s11102-005- 1172-7
13. G. Arnaldi, V.M. Scandali, L. Trementino, M. Cardinaletti, G. Appolloni, M. Boscaro, Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology 92(Suppl 1), 86-90 (2010). doi: 10.1159/000314213
14. B.M. Biller, A. Colao, S. Petersenn, V.S. Bonert, M. Boscaro, Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr. Disord. 10, 10 (2010). doi: 10.1186/1472-6823-10-10
15. M. Boscaro, N. Sonino, A. Scarda, L. Barzon, F. Fallo, M.T. Sartori, G.M. Patrassi, A. Girolami, Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J. Clin. Endocrinol. Metab. 87(8), 3662-3666 (2002)
16. E. Valassi, B.M. Biller, A. Klibanski, M. Misra, Adipokines and cardiovascular risk in Cushing's syndrome. Neuroendocrinology 95(3), 187-206 (2012). doi: 10.1159/000330416
17. M. De Leo, R. Pivonello, R.S. Auriemma, A. Cozzolino, P. Vitale, C. Simeoli, M.C. De Martino, G. Lombardi, A. Colao, Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology 92(Suppl 1), 50-54 (2010). doi: 10.1159/000318566
18. R. Pivonello, M.C. De Martino, M. De Leo, L. Tauchmanova, A. Faggiano, G. Lombardi, A. Colao, Cushing's syndrome: aftermath of the cure. Arq. Bras. Endocrinol. Metab. 51(8), 1381-1391 (2007)
19. R.N. Clayton, D. Raskauskiene, R.C. Reulen, P.W. Jones, Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J. Clin. Endocrinol. Metab. 96(3), 632-642 (2011). doi: 10.1210/jc.2010-1942
20. J.W. Findling, H. Raff, Cushing's syndrome: important issues in diagnosis and management. J. Clin. Endocrinol. Metab. 91(10), 3746-3753 (2006). doi: 10.1210/jc.2006-0997
21. N.A. Tritos, B.M. Biller, B. Swearingen, Management of Cushing disease. Nat. Rev. Endocrinol. 7(5), 279-289 (2011). doi: 10.1038/nrendo.2011.12
22. D.E. Schteingart, Drugs in the medical treatment of Cushing's syndrome. Expert. Opin. Emerg. Drugs 14(4), 661-671 (2009). doi: 10.1517/14728210903413522
23. M. Fleseriu, B.M. Biller, J.W. Findling, M.E. Molitch, D.E. Schteingart, C. Gross, Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J. Clin. Endocrinol. Metab. 97(6), 2039-2049 (2012). doi: 10.1210/jc.2011-3350
24. Ma. Fleseriu, DLa Loriaux, WHb Ludlam, Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful. Curr. Opin. Endocrinol. Diabetes Obes. 14(4), 323-328 (2007)
25. T. Mancini, T. Porcelli, A. Giustina, Treatment of Cushing disease: overview and recent findings. Ther. Clin. Risk Manag. 6, 505-516 (2010). doi: 10.2147/TCRM.S12952
26. F. Castinetti, M. Fassnacht, S. Johanssen, M. Terzolo, P. Bouchard, P. Chanson, C. Do Cao, I. Morange, A. Pico, S. Ouzounian, J. Young, S. Hahner, T. Brue, B. Allolio, B. Conte-Devolx, Merits and pitfalls of mifepristone in Cushing's syndrome. Eur. J. Endocrinol. 160(6), 1003-1010 (2009). doi: 10.1530/EJE-09-0098
27. S. Johanssen, B. Allolio, Mifepristone (RU 486) in Cushing's syndrome. Eur. J. Endocrinol. 157(5), 561-569 (2007). doi: 10.1530/eje-07-0458
28. D.M. Prevedello, N. Pouratian, J. Sherman, J.A. Jane Jr, M.L. Vance, M.B. Lopes, E.R. Laws Jr, Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J. Neurosurg. 109(4), 751-759 (2008). doi: 10.3171/JNS/2008/109/10/0751
29. S. Salenave, B. Gatta, S. Pecheur, F. San-Galli, A. Visot, P. Lasjaunias, P. Roger, J. Berge, J. Young, A. Tabarin, P. Chanson, Pituitary magnetic resonance imaging findings do not influence surgical outcome in adrenocorticotropin-secreting microadenomas. J. Clin. Endocrinol. Metab. 89(7), 3371-3376 (2004)
30. R.A. Alwani, W.W. de Herder, M.O. van Aken, J.H. van den Berge, E.J. Delwel, A.H. Dallenga, F.H. De Jong, S.W. Lamberts, A.J. van der Lely, R.A. Feelders, Biochemical predictors of outcome of pituitary surgery for Cushing's disease. Neuroendocrinology 91(2), 169-178 (2010). doi: 10.1159/000258677
31. C.G. Patil, D.M. Prevedello, S.P. Lad, M.L. Vance, M.O. Thorner, L. Katznelson, E.R. Laws Jr, Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J. Clin. Endocrinol. Metab. 93(2), 358-362 (2008). doi: 10.1210/jc.2007-2013
32. A.M. Pereira, J. Tiemensma, J.A. Romijn, Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology 92(Suppl 1), 65-70 (2010). doi: 10.1159/000314317
33. F. Roelfsema, N.R. Biermasz, A.M. Pereira, Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1), 71-83 (2012). doi: 10.1007/s11102-011-0347-7
34. A.B. Atkinson, A. Kennedy, M.I. Wiggam, D.R. McCance, B. Sheridan, Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin. Endocrinol. (Oxf.) 63(5), 549-559 (2005). doi: 10.1111/j.1365-2265.2005.02380.x
35. L.S. Blevins, J.H. Christy, M. Khajavi, G.T. Tindall, Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J. Clin. Endocrinol. Metab. 83(1), 63-67 (1998). doi: 10.1210/jc.83.1.63
36. F. Esposito, J.R. Dusick, P. Cohan, P. Moftakhar, D. McArthur, C. Wang, R.S. Swerdloff, D.F. Kelly, Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J. Clin. Endocrinol. Metab. 91(1), 7-13 (2006). doi: 10.1210/jc.2005-1204
37. B.M. Hofmann, M. Hlavac, J. Kreutzer, G. Grabenbauer, R. Fahlbusch, Surgical treatment of recurrent Cushing's disease. Neurosurgery 58(6), 1108-1118 (2006). doi: 10.1227/01.NEU.0000215945.26764.92. discussion 1108-1118
38. C.G. Patil, A. Veeravagu, D.M. Prevedello, L. Katznelson, M.L. Vance, E.R. Laws Jr, Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease. Neurosurgery 63(2), 266-270 (2008). doi: 10.1227/01.NEU. 0000313117.35824.9F. discussion 270-271
39. M. Fleseriu, S. Petersenn, Medical management of Cushing's disease: what is the future? Pituitary 15(3), 330-341 (2012). doi: 10.1007/s11102-012-0397-5
40. D.E. Schteingart, Conventional and novel strategies in the treatment of adrenocortical cancer. Braz. J. Med. Biol. Res. 33(10), 1197-1200 (2000)
41. M. Fassnacht, R. Libe, M. Kroiss, B. Allolio, Adrenocortical carcinoma: a clinician's update. Nat. Rev. Endocrinol. 7(6), 323-335 (2011). doi: 10.1038/nrendo.2010.235
42. M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti, S. Welin, C. Schade-Brittinger, A. Lacroix, B. Jarzab, H. Sorbye, D.J. Torpy, V. Stepan, D.E. Schteingart, W. Arlt, M. Kroiss, S. Leboulleux, P. Sperone, A. Sundin, I. Hermsen, S. Hahner, H.S. Willenberg, A. Tabarin, M. Quinkler, C. de la Fouchardiere, M. Schlumberger, F. Mantero, D. Weismann, F. Beuschlein, H. Gelderblom, H. Wilmink, M. Sender, M. Edgerly, W. Kenn, T. Fojo, H.H. Muller, B. Skogseid, Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366(23), 2189-2197 (2012). doi: 10.1056/NEJMoa1200966
43. R. Giordano, F. Guaraldi, R. Berardelli, I. Karamouzis, V. D'Angelo, E. Marinazzo, A. Picu, E. Ghigo, E. Arvat, Glucose metabolism in patients with subclinical Cushing's syndrome. Endocrine 41(3), 415-423 (2012). doi: 10.1007/s12020-012-9628-9
44. L.M. Kettel, Clinical applications of the antiprogestins. Clin. Obstet. Gynecol. 38(4), 921-934 (1995)
45. P.M. Stewart, N. Krone, The adrenal cortex, in Williams Textbook of Endocrinology, Chap. 15, ed. by S. Melmed, K.S. Polonsky, P.R. Larsen, H.M. Kronenberg (Elsevier/Saunders, Philadelphia, 2012)
46. O. Sartor, G.B. Cutler Jr, Mifepristone: treatment of Cushing's syndrome. Clin. Obstet. Gynecol. 39(2), 506-510 (1996)
47. F. Cadepond, A. Ulmann, E.E. Baulieu, RU486 (mifepristone): mechanisms of action and clinical uses. Annu. Rev. Med. 48, 129-156 (1997). doi: 10.1146/annurev.med.48.1.129
48. E.E. Baulieu, Contragestion with RU 486: a new approach to postovulatory fertility control. Acta Obstet. Gynecol. Scand. Suppl. 149, 5-8 (1989)
49. M.C. Raux-Demay, T. Pierret, M. Bouvier d'Yvoire, X. Bertagna, F. Girard, Transient inhibition of RU 486 antiglucocorticoid action by dexamethasone. J. Clin. Endocrinol. Metab. 70(1), 230-233 (1990)
50. L. Laue, W. Gallucci, D.L. Loriaux, R. Udelsman, G.P. Chrousos, The antiglucocorticoid and antiprogestin steroid RU 486: its glucocorticoid agonist effect is inadequate to prevent adrenal insufficiency in primates. J. Clin. Endocrinol. Metab. 67(3), 602-606 (1988)
51. I. Foldesi, G. Falkay, L. Kovacs, Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study. Contraception 54(1), 27-32 (1996)
52. S. Kawai, L.K. Nieman, D.D. Brandon, R. Udelsman, D.L. Loriaux, G.P. Chrousos, Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. J. Pharmacol. Exp. Ther. 241(2), 401-406 (1987)
53. O. Heikinheimo, T. Raivio, H. Honkanen, S. Ranta, O.A. Janne, Termination of pregnancy with mifepristone and prostaglandin suppresses transiently circulating glucocorticoid bioactivity. J. Clin. Endocrinol. Metab. 88(1), 323-326 (2003)
54. M. Basina, H. Liu, A.R. Hoffman, D. Feldman, Successful long-term treatment of Cushings disease with mifepristone (RU486). Endocr. Pract. 1-19 (2012). doi: 10.4158/EP11391.CR
55. B. Beaufrere, L. de Parscau, P. Chatelain, Y. Morel, M. Aguercif, R. Francois, RU 486 administration in a child with Cushing's syndrome. Lancet 2(8552), 217 (1987)
56. Y.M. Bilgin, H.E. van der Wiel, H.R. Fischer, W.W. De Herder, Treatment of severe psychosis due to ectopic Cushing's syndrome. J. Endocrinol. Invest. 30(9), 776-779 (2007)
57. P.A. Cassier, S. Abou-Amara-Olivieri, P. Artru, M.G. Lapalus, J.P. Riou, C. Lombard-Bohas, Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases. Eur. J. Endocrinol. 158(6), 935-938 (2008). doi: 10.1530/EJE-07-0792
58. G. Chrousos, L. Laue, L. Nieman, R. Udelsman, S. Kawai, D. Loriaux, Clinical Applications of RU 486, A Prototype Glucocorticoid and Progestin Antagonist (Raven Press, New York, 1989)
59. J.W. Chu, D.F. Matthias, J. Belanoff, A. Schatzberg, A.R. Hoffman, D. Feldman, Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J. Clin. Endocrinol. Metab. 86(8), 3568-3573 (2001)
60. P. Contreras, R. Caviedas, R. Rojas, M. Lopez, Adrenal cancer: tumor regression with ketoconazole or mifepristone (RU 486): in vivo and in vitro evidence supporting tumoral hormone dependency. In: 69th Annual Endocrine Society Meeting, Indianapolis (1987), p. 23
61. J.E. Donckier, L.A. Michel, A. Berbinschi, P.M. De Coster, J.F. De Plaen, J.M. Ketelslegers, M. Buysschaert, Late recurrence of operated adrenocortical carcinoma: atrial natriuretic factor before and after treatment with mitotane. Surgery 105(5), 690-692 (1989)
62. R.S. Newfield, I.M. Spitz, C. Isacson, M.I. New, Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin. Endocrinol. (Oxf.) 54(3), 399-404 (2001)
63. L.K. Nieman, G.P. Chrousos, C. Kellner, I.M. Spitz, B.C. Nisula, G.B. Cutler, G.R. Merriam, C.W. Bardin, D.L. Loriaux, Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J. Clin. Endocrinol. Metab. 61(3), 536-540 (1985)
64. L.K. Nieman, R. Udelsman, D.L. Loriaux, G.P. Chrousos, Antiglucocorticoids: Basic and clinical studies, in Recent Advances in Adrenal Regulation and Function, vol. 40, ed. by R. D'Agata, G.P. Chrousos (Raven Press, New York, 1987), pp. 235-258
65. J.K. Oosterhuis, G. van den Berg, W.E. Monteban-Kooistra, J.J. Ligtenberg, J.E. Tulleken, J.H. Meertens, J.G. Zijlstra, Life-threatening Pneumocystis jiroveci pneumonia following treatment of severe Cushing's syndrome. Neth. J. Med. 65(6), 215-217 (2007)
66. A.J. van der Lely, K. Foeken, R.C. van der Mast, S.W. Lamberts, Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann. Intern. Med. 114(2), 143-144 (1991)
67. C. de Bruin, L.J. Hofland, L.K. Nieman, P.M. van Koetsveld, A.M. Waaijers, D.M. Sprij-Mooij, M. van Essen, S.W. Lamberts, W.W. de Herder, R.A. Feelders, Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion. J. Clin. Endocrinol. Metab. 97(2), 455-462 (2012). doi: 10.1210/jc.2011-1264
68. F. Castinetti, M. Nagai, I. Morange, H. Dufour, P. Caron, P. Chanson, C. Cortet-Rudelli, J.M. Kuhn, B. Conte-Devolx, J. Regis, T. Brue, Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J. Clin. Endocrinol. Metab. 94(9), 3400-3407 (2009). doi: 10.1210/jc.2008-2772
69. F. Castinetti, I. Morange, P. Jaquet, B. Conte-Devolx, T. Brue, Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur. J. Endocrinol. 158(1), 91-99 (2008). doi: 10.1530/EJE-07-0514
70. D.L. Batista, X. Zhang, R. Gejman, P.J. Ansell, Y. Zhou, S.A. Johnson, B. Swearingen, E.T. Hedley-Whyte, C.A. Stratakis, A. Klibanski, The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J. Clin. Endocrinol. Metab. 91(11), 4482-4488 (2006). doi: 10.1210/jc.2006-1245
71. Y. Greenman, S. Melmed, Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J. Clin. Endocrinol. Metab. 79(3), 724-729 (1994)
72. Y. Greenman, S. Melmed, Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J. Clin. Endocrinol. Metab. 78(2), 398-403 (1994)
73. L.J. Hofland, J. van der Hoek, R. Feelders, M.O. van Aken, P.M. van Koetsveld, M. Waaijers, D. Sprij-Mooij, C. Bruns, G. Weckbecker, W.W. de Herder, A. Beckers, S.W. Lamberts, The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur. J. Endocrinol. 152(4), 645-654 (2005). doi: 10.1530/eje.1.01876
74. G.M. Miller, J.M. Alexander, H.A. Bikkal, L. Katznelson, N.T. Zervas, A. Klibanski, Somatostatin receptor subtype gene expression in pituitary adenomas. J. Clin. Endocrinol. Metab. 80(4), 1386-1392 (1995)
75. S. Nielsen, S. Mellemkjaer, L.M. Rasmussen, T. Ledet, J. Astrup, J. Weeke, J.O. Jorgensen, Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas. J. Clin. Endocrinol. Metab. 83(8), 2997-3000 (1998)
76. R. Panetta, Y.C. Patel, Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci. 56(5), 333-342 (1995)
77. A. Ben-Shlomo, H. Schmid, K. Wawrowsky, O. Pichurin, E. Hubina, V. Chesnokova, N.A. Liu, M. Culler, S. Melmed, Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J. Clin. Endocrinol. Metab. 94(11), 4342-4350 (2009). doi: 10.1210/jc.2009-1311
78. B. Ambrosi, D. Bochicchio, C. Fadin, P. Colombo, G. Faglia, Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. J. Endocrinol. Invest. 13(3), 257-261 (1990)
79. G.K. Stalla, S.J. Brockmeier, U. Renner, C. Newton, M. Buchfelder, J. Stalla, O.A. Muller, Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur. J. Endocrinol. 130(2), 125-131 (1994)
80. S.W. Lamberts, J. Zuyderwijk, F. den Holder, P. van Koetsveld, L. Hofland, Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 50(1), 44-50 (1989)
81. C. Bruns, I. Lewis, U. Briner, G. Meno-Tetang, G. Weckbecker, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146(5), 707-716 (2002). doi: 146707. [pii]
82. H.A. Schmid, P. Schoeffter, Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl 1), 47-50 (2004). doi: 10.1159/000080741
83. M. Boscaro, W.H. Ludlam, B. Atkinson, J.E. Glusman, S. Petersenn, M. Reincke, P. Snyder, A. Tabarin, B.M. Biller, J. Findling, S. Melmed, C.H. Darby, K. Hu, Y. Wang, P.U. Freda, A.B. Grossman, L.A. Frohman, J. Bertherat, Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J. Clin. Endocrinol. Metab. 94(1), 115-122 (2009). doi: 10.1210/jc.2008-1008
84. A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, UDipl-Biol Schoenherr, D. Mills, L.R. Salgado, B.M.K. Biller, A 12-month phase 3 study of pasireotide in Cushing's disease. N. Engl. J. Med. 366(10), 914-924 (2012). doi: 10.1056/NEJMoa1105743
85. J.W. Miller, L. Crapo, The medical treatment of Cushing's syndrome. Endocr. Rev. 14(4), 443-458 (1993)
86. A.C. Hale, P.J. Coates, I. Doniach, T.A. Howlett, A. Grossman, L.H. Rees, G.M. Besser, A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing's disease. Clin. Endocrinol. (Oxf.) 28(2), 215-223 (1988)
87. H.P. Koppeschaar, R.J. Croughs, J.H. Thijssen, F. Schwarz, Response to neurotransmitter modulating drugs in patients with Cushing's disease. Clin. Endocrinol. (Oxf.) 25(6), 661-667 (1986)
88. R. Pivonello, M.C. De Martino, P. Cappabianca, M. De Leo, A. Faggiano, G. Lombardi, L.J. Hofland, S.W. Lamberts, A. Colao, The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J. Clin. Endocrinol. Metab. 94(1), 223-230 (2009). doi: 10.1210/jc.2008-1533
89. A. Godbout, M. Manavela, K. Danilowicz, H. Beauregard, O.D. Bruno, A. Lacroix, Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur. J. Endocrinol. 163(5), 709-716 (2010). doi: 10.1530/EJE-10-0382
90. D. Giacomini, M. Paez-Pereda, M. Theodoropoulou, M. Labeur, D. Refojo, J. Gerez, A. Chervin, S. Berner, M. Losa, M. Buchfelder, U. Renner, G.K. Stalla, E. Arzt, Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 147(1), 247-256 (2006). doi: 10.1210/en.2005-0958
91. V. Castillo, D. Giacomini, M. Paez-Pereda, J. Stalla, M. Labeur, M. Theodoropoulou, F. Holsboer, A.B. Grossman, G.K. Stalla, E. Arzt, Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 147(9), 4438-4444 (2006). doi: 10.1210/en.2006-0414
92. F. Pecori Giraldi, A.G. Ambrogio, M. Andrioli, F. Sanguin, I. Karamouzis, S.M. Corsello, C. Scaroni, E. Arvat, A. Pontercorvi, F. Cavagnini, Potential role for retinoic acid in patients with Cushing's disease. J. Clin. Endocrinol. Metab. 97(10), 3577-3583 (2012). doi: 10.1210/jc.2012-2328
93. J. Heyn, C. Geiger, C.L. Hinske, J. Briegel, F. Weis, Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate. Pituitary 15(2), 117-125 (2012). doi: 10.1007/s11102-011-0314-3
94. V.A. Preda, J. Sen, N. Karavitaki, A.B. Grossman, THERAPY IN ENDOCRINE DISEASE: etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur. J. Endocrinol. 167(2), 137-143 (2012). doi: 10.1530/EJE-12-0274
95. D. Feldman, Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr. Rev. 7(4), 409-420 (1986)
96. N. Sonino, The use of ketoconazole as an inhibitor of steroid production. N. Engl. J. Med. 317(13), 812-818 (1987)
97. J.H. Lewis, H.J. Zimmerman, G.D. Benson, K.G. Ishak, Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86(3), 503-513 (1984)
98. L.K. Nieman, Medical therapy of Cushing's disease. Pituitary 5(2), 77-82 (2002)
99. C. Baudry, J. Coste, R. Bou Khalil, S. Silvera, L. Guignat, J. Guibourdenche, H. Abbas, P. Legmann, X. Bertagna, J. Bertherat, Efficiency and tolerance of mitotane in Cushing's Disease in 76 patients from a single center. Eur. J. Endocrinol. (2012). doi: 10.1530/EJE-12-0358
100. D.E. Schteingart, H.S. Tsao, C.I. Taylor, A. McKenzie, R. Victoria, B.A. Therrien, Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann. Intern. Med. 92(5), 613-619 (1980)
101. J.P. Luton, J.A. Mahoudeau, P. Bouchard, P. Thieblot, M. Hautecouverture, D. Simon, M.H. Laudat, Y. Touitou, H. Bricaire, Treatment of Cushing's disease by O, p'DDD. Survey of 62 cases. N. Engl. J. Med. 300(9), 459-464 (1979). doi: 10.1056/NEJM197903013000903
102. S. Leiba, R. Weinstein, B. Shindel, M. Lapidot, E. Stern, H. Levavi, Y. Rusecki, A. Abramovici, The protracted effect of o, p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann. Endocrinol. (Paris) 50(1), 49-53 (1989)
103. R.A. Feelders, C. de Bruin, A.M. Pereira, J.A. Romijn, R.T. Netea-Maier, A.R. Hermus, P.M. Zelissen, R. van Heerebeek, F.H. de Jong, A.J. van der Lely, W.W. de Herder, L.J. Hofland, S.W. Lamberts, Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N. Engl. J. Med. 362(19), 1846-1848 (2010). doi: 10.1056/NEJMc1000094
104. H. Bode, M. Seiz, A. Lammert, M.A. Brockmann, W. Back, H.P. Hammes, C. Thome, SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp. Clin. Endocrinol. Diabetes 118(10), 760-763 (2010). doi: 10.1055/s-0030-1253419
105. P. Kamenicky, C. Droumaguet, S. Salenave, A. Blanchard, C. Jublanc, J.F. Gautier, S. Brailly-Tabard, S. Leboulleux, M. Schlumberger, E. Baudin, P. Chanson, J. Young, Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J. Clin. Endocrinol. Metab. 96(9), 2796-2804 (2011). doi: 10.1210/jc.2011-0536
106. G. Assie, H. Bahurel, J. Coste, S. Silvera, M. Kujas, M.A. Dugue, F. Karray, B. Dousset, J. Bertherat, P. Legmann, X. Bertagna, Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's Syndrome. J. Clin. Endocrinol. Metab. 92(1), 172-179 (2007). doi: 10.1210/jc.2006-1328